KCP
KYTX icon

Kera Capital Partners’s Kyverna Therapeutics KYTX Stock Holding History

Kera Capital Partners’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$933K Sell
108,083
-24,520
-18% -$204K 0.11% 96
2025
Q4 		$1.06M Sell
132,603
-289,321
-69% -$2.15M 0.13% 84
2025
Q3 		$2.53M Hold
421,924
– – 0.38% 54
2025
Q2 		$1.3M Buy
421,924
+45,738
+12% +$113K 0.26% 56
2025
Q1 		$726K Buy
376,186
+55
+0% +$163 0.22% 52
2024
Q4 		$1.41M Buy
+376,131
New +$1.8M 0.41% 44

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Kera Capital Partners's KYTX Position: Q1 2026 in Review

Kera Capital Partners reduced its Kyverna Therapeutics (KYTX) stake by 18% in Q1 2026, selling an estimated $204K and leaving 108,083 shares worth $933K. The position accounts for 0.11% of the portfolio, ranked #96.

Kera Capital Partners first reported a position in KYTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $2.53M in Q3 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Kera Capital Partners held 108,083 shares of Kyverna Therapeutics worth $933K as of Q1 2026.
  • Kera Capital Partners sold 24,520 Kyverna Therapeutics shares in Q1 2026, an estimated $204K.
  • Kyverna Therapeutics made up 0.11% of Kera Capital Partners's portfolio in Q1 2026, its #96 holding.
  • Kera Capital Partners first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Kera Capital Partners's Kyverna Therapeutics position peaked at $2.53M in Q3 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Kera Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.